MX9203380A - Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen.

Info

Publication number
MX9203380A
MX9203380A MX9203380A MX9203380A MX9203380A MX 9203380 A MX9203380 A MX 9203380A MX 9203380 A MX9203380 A MX 9203380A MX 9203380 A MX9203380 A MX 9203380A MX 9203380 A MX9203380 A MX 9203380A
Authority
MX
Mexico
Prior art keywords
carbazolil
oxi
propanolamine
derivatives
contain
Prior art date
Application number
MX9203380A
Other languages
English (en)
Spanish (es)
Inventor
Fritz Wiedemann
Wolfgang Kampe
Max Thiel
Gisbert Sponer
Egon Roesch
Karl Dietmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9203380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of MX9203380A publication Critical patent/MX9203380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX9203380A 1978-04-13 1992-06-25 Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen. MX9203380A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
MX9203380A true MX9203380A (es) 1992-09-01

Family

ID=6036838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203380A MX9203380A (es) 1978-04-13 1992-06-25 Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen.

Country Status (23)

Country Link
US (1) US4503067A (en:Method)
EP (1) EP0004920B1 (en:Method)
JP (2) JPS54157558A (en:Method)
AT (1) AT375639B (en:Method)
AU (1) AU522975B2 (en:Method)
BG (1) BG61419B2 (en:Method)
CA (1) CA1129416A (en:Method)
CS (2) CS227007B2 (en:Method)
DD (1) DD143607A5 (en:Method)
DE (2) DE2815926A1 (en:Method)
DK (1) DK154555C (en:Method)
ES (1) ES479396A1 (en:Method)
FI (1) FI70406C (en:Method)
HK (1) HK2385A (en:Method)
HU (1) HU179433B (en:Method)
IL (1) IL57020A (en:Method)
LT (1) LT2628B (en:Method)
LU (1) LU88320I2 (en:Method)
MX (1) MX9203380A (en:Method)
NL (1) NL930110I2 (en:Method)
SG (1) SG52284G (en:Method)
SU (1) SU810079A3 (en:Method)
ZA (1) ZA791732B (en:Method)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
WO1994020096A1 (en) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
JP2001504804A (ja) * 1996-08-23 2001-04-10 ベーリンガー・マンハイム・ファーマシューティカルズ・コーポレイション−スミスクライン・ベックマン・コーポレイション・リミテッド・パートナーシップ・ナンバー１ Ｆａｓ発現阻害方法
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
EP0946172A4 (en) * 1996-10-09 2002-05-22 Boehringer Mannheim Pharm Corp METHOD OF INHIBITING STRESS-ACTIVATED KINASE PROTEINS
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
KR20010031952A (ko) * 1997-11-12 2001-04-16 에드워드 부두지엠 카르베디롤을 위한 신규 경구 투여형
HU9702209D0 (en) * 1997-11-24 1998-01-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical product
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
AU3522399A (en) * 1998-04-09 1999-11-01 Roche Diagnostics Gmbh Carvedilol-galenics
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6291506B1 (en) 1998-08-04 2001-09-18 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
JP2003514019A (ja) 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
ES2227206T3 (es) * 2000-04-03 2005-04-01 F. Hoffmann-La Roche Ag Soluciones concentradas de carvedilol.
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
MXPA02012795A (es) 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2002078692A1 (en) * 2001-04-02 2002-10-10 Smithkline Beecham Corporation Method of treatment
IN191028B (en:Method) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
ATE328595T1 (de) * 2001-07-13 2006-06-15 Smithkline Beecham Corp Carvedilolpolymorph
AU2002323135A1 (en) * 2001-08-14 2003-03-03 Variant Holdings, Llc. System for marketing goods and services utilizing computerized central and remote facilities
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
MXPA04002826A (es) * 2001-09-28 2004-07-02 Hoffmann La Roche Formas pseudopolimorficas de carvedilol.
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HRP20040673A2 (en) 2002-01-15 2005-06-30 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
WO2003092626A2 (en) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
US20050261335A1 (en) * 2002-05-03 2005-11-24 Wei Chen Carvedilol formulations
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
WO2004002419A2 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
KR20040010306A (ko) * 2002-07-22 2004-01-31 (주)나노하이브리드 이트라코나졸, 사이클로스포린 또는 카르베딜올과 층상형규산염의 혼성체 및 그 제조 방법
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
US7468442B2 (en) * 2003-04-21 2008-12-23 Matrix Laboratories Ltd. Process for the preparation of carvedilol form-II
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
ES2662903T3 (es) 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
WO2005115981A2 (en) * 2004-04-22 2005-12-08 Usv Limited A process for the preparation of 1-(9h-carbazol-4-yloxy)-3-2-(-methoxyphenoxy)-ethyl amino-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
JP2008521805A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
CN100591668C (zh) * 2004-12-09 2010-02-24 Zach系统股份公司 制备卡维地洛及其对映异构体的方法
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
EP1781611A1 (en) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
ZA200803226B (en) * 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
WO2008038301A1 (en) * 2006-09-26 2008-04-03 Morepen Laboratories Limited A process for the preparation of carvedilol
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009024997A1 (en) * 2007-08-21 2009-02-26 Lupin Limited Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
US20090076283A1 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
EP2259801B1 (en) 2008-03-04 2012-01-04 Lupin Limited Stable pharmaceutical compositions of carvedilol
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
WO2009115906A2 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. An improved process for preparation of carvedilol involving halohydrin derivative
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (en) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Process for preparation of amorphous carvedilol phosphate
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
IN2014CN04350A (en:Method) 2011-12-16 2015-09-04 3M Innovative Properties Co
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8492426B1 (en) 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
ES3007652T3 (en) 2019-01-18 2025-03-20 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法
CN115960032A (zh) * 2021-10-08 2023-04-14 复旦大学 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives

Also Published As

Publication number Publication date
ES479396A1 (es) 1980-04-16
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
HU179433B (en) 1982-10-28
AU522975B2 (en) 1982-07-08
FI70406B (fi) 1986-03-27
SU810079A3 (ru) 1981-02-28
AU4582079A (en) 1979-10-18
JPH0123462B2 (en:Method) 1989-05-02
NL930110I2 (nl) 1994-12-01
CS420091A3 (en) 1992-04-15
NL930110I1 (nl) 1993-10-18
CS227007B2 (en) 1984-04-16
EP0004920B1 (de) 1981-08-05
DK154555B (da) 1988-11-28
DK154555C (da) 1989-06-19
DE2815926A1 (de) 1979-10-18
LU88320I2 (de) 1994-05-04
JPS63258416A (ja) 1988-10-25
DK141979A (da) 1979-10-14
LT2628B (lt) 1994-04-25
IL57020A (en) 1982-07-30
US4503067A (en) 1985-03-05
CA1129416A (en) 1982-08-10
BG61419B2 (bg) 1997-07-31
FI70406C (fi) 1986-09-19
DE2960553D1 (en) 1981-11-05
EP0004920A1 (de) 1979-10-31
DD143607A5 (de) 1980-09-03
FI791142A7 (fi) 1979-10-14
SG52284G (en) 1985-03-29
ZA791732B (en) 1980-05-28
AT375639B (de) 1984-08-27
JPS54157558A (en) 1979-12-12
ATA276279A (de) 1984-01-15

Similar Documents

Publication Publication Date Title
MX9203380A (es) Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen.
MX9203107A (es) 6-n-propil-8-metoximetil o metilmercaptometil-ergolinas y composiciones farmaceuticas que las contienen.
MX9203363A (es) Nuevos derivados de acido 3-aminopropansulfonico y composiciones farmaceuticas que los contienen.
MX9203226A (es) Derivados de fenetanolamina y composicion farmaceutica que los contiene.
MX9203368A (es) Muramilpeptidos lipofilicos y composiciones farmaceuticas que los contienen.
MX9203027A (es) Derivados heterociclicos de acilaminotiazoles y composicines farmaceuticas que los contienen.
AR225458A1 (es) Derivados de 1-(diclorofenil)-3-alquil-delta2-1,2,4-triazolin-5-ona y composiciones herbicidas que los contienen
MX9203040A (es) Derivados de quinona y composicion farmaceutica que los contiene.
IT7925182A0 (it) Derivati di spiro-ossazolidindioni e composizioni farmaceutiche che li contengono.
MX9202910A (es) Nuevos derivados de dihidropiridina y composicion farmaceutica que los contiene.
MX9203126A (es) Derivados de sulfonilurea y composiciones farmaceuticas que los contienen.
AR240697A1 (es) Derivados de acido mandelico y nitilos mandelicos y composiciones que los contienen
IT8022265A0 (it) Derivati di alchil-chetoesopiranosidi.
MX9202935A (es) Derivados de 2,3-dihidro-1h-indeno y composicion farmaceutica que los contiene.
MX9203148A (es) 2,6-dialcoxipenzamidas y composiciones farmaceuticas que las contienen.
MX9203639A (es) 3-fenoxi-1-azetidincarboxamidas y composiciones farmaceuticas que las contienen.
AR227787A1 (es) Esteres pirazol-(4)-ilicos de acidos n-acil-n-metil-carbamicos,procedimientos para su obtencion y composiciones plaguicidas que los contienen
MX9203383A (es) Nuevos derivados de piridobenzoindol y composiciones farmaceuticas que los contienen.
MX9203021A (es) Derivados de carbostirilo y composicion farmaceutica que los contiene.
IT1122180B (it) Derivati di 1-fenil-1-propanolo
DK461579A (da) Farmeceutisk komposition indeholdende en aryltrifluorethanol
AR227635A1 (es) M-anilidouretanos y las composiciones herbicidas que los contienen
IT7950202A0 (it) Derivati alfa-aril-alfa alfa-bisomega-ammino bisostituiti alchilacetammidici ditati di proprieta'farmacologiche antiaritmia
AR224136A1 (es) Derivados de 2-oxo-4,5,5-trisustituido-3-tiazolon-0-(carbamoil sustituido,-oxima,agentes que los contienen y procedimiento para su preparacion
IT1162702B (it) Derivati di 11-alcanoil-4"-isonitril-oleandomicina